CONCLUSIONS: These findings underscore the critical role of the METTL16–MSMO1 axis in driving cholesterol metabolic reprogramming that fuels MAPK-p38/NF-κB oncogenic signaling in CRC, highlighting promising biomarkers and therapeutic targets for improved disease management. This evidence concerns the gene METTL16 and colorectal carcinoma.